Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 78

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 78
---
 November
7, 2024 at 12:01 a.m. Eastern Time, a reverse split of the Company’s common stock at a ratio of one-for-35 (the “November
2024 Reverse Stock Split”).

All per share amounts (including exercise prices)
and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect both the August
2024 Reverse Stock Split and the November 2024 Reverse Stock Split.

The August 2024 Reverse Stock Split and the November
2024 Reverse Stock Split resulted in a proportionate adjustment to the per share conversion or exercise price and the number of shares
of common stock issuable upon the conversion or exercise of outstanding preferred stock, stock options and warrants, as well as the number
of shares of common stock eligible for issuance under the Omnibus Plan.

Note 8 - Common Stock Options, Restricted Stock
Units and Restricted Stock

Common Stock Options

Stock options are awarded to the Company’s
employees, consultants and non-employee members of the board of directors under the Omnibus Plan and are generally granted with an exercise
price equal to the market price of the Company’s common stock at the date of grant. There were no issuances of stock options in
the quarter ended September 30, 2025. A summary of option activity under the Company’s Omnibus Plan as of September 30, 2025, and
changes during the quarter then ended, is presented below:

             Weighted          Weighted   Average          Average   Remaining      Number of   Exercise   Contractual      Options   Price   Term (Years)   Balance outstanding at December 31, 2024   278   $30,628.90    5.35   Granted   -    -    -   Exercised   -    -    -   Forfeited   -    -    -   Cancelled or expired   (12)   120,055.83    -   Balance outstanding at September 30, 2025   266   $26,594.61    4.80   Exercisable at September 30, 2025   229   $29,710.19    4.39  

Restricted